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e ingestion of excessive amounts of saturated fatty acids (SFAs) and transfatty acids (TFAs) is considered to be a risk factor for
cardiovascular diseases, insulin resistance, dyslipidemia, and obesity.e focus of this paper was to elucidate the in�uence of dietary
SFA and TFA intake on the promotion of lipotoxicity to the liver and cardiovascular, endothelial, and gut microbiota systems, as
well as on insulin resistance and endoplasmic reticulum stress. e saturated and transfatty acids favor a proin�ammatory state
leading to insulin resistance.ese fatty acids can be involved in several in�ammatory pathways, contributing to disease progression
in chronic in�ammation, autoimmunity, allergy, cancer, atherosclerosis, hypertension, and heart hypertrophy as well as other
metabolic and degenerative diseases. As a consequence, lipotoxicity may occur in several target organs by direct eﬀects, represented
by in�ammation pathways, and through indirect eﬀects, including an important alteration in the gut microbiota associated with
endotoxemia. Interactions between these pathways may perpetuate a feedback process that exacerbates an in�ammatory state. e
importance of lifestyle modi�cation, including an improved diet, is recommended as a strategy for treatment of these diseases.
1. Introduction
Fat is an important component of the normal human diet. It
is a source of energy and provides essential fatty acids and
fat-soluble vitamins. However, several fatty acids in fats,
especially saturated fatty acids (SFAs) and trans fatty acids
(TFAs) may have adverse eﬀects on human health [1–3].
In the human diet, SFAs are derived from animal sources,
while TFAs originate in meat and milk from ruminant
animals and result from bacterial biohydrogenation of unsat-
urated fatty acids in the rumen [4]. In addition, partial
hydrogenation of unsaturated fatty acids in vegetable oils
during the industrial production of certain foods produces
TFA [5]. Small amounts of TFA are produced during the
processes used to deodori�e or re�ne vegetable oils to make
the products more stable and robust and thus easier to handle
or store [6, 7].
Most TFAs have physical properties similar to SFAs [8].
More speci�cally, monounsaturated TFA isomers with 18-
carbon chain lengths (trans-18 : 1) are among the most
predominant TFAs present in the human diet [9, 10]. It is
well established that intake of SFA and TFA is a signi�cant
risk factor for cardiovascular diseases (CVD) as well as
in�ammation, insulin resistance, and obesity. ese fatty
acids also induce endothelial dysfunction and an unfavorable
blood lipid pro�le, including increased LDL-c and decreased
HDL-c levels [2, 11, 12].
High SFA and TFA intake, the typical dietary pattern of
western populations, favors a proin�ammatory status that
contributes to development of insulin resistance. Roles for
SFA and TFA intake have been demonstrated in several
in�ammatory pathways and result from imbalances in the
highly interconnected lipid signaling pathways that con-
tribute to disease progression in chronic in�ammation, auto-
immunity, allergy, cancer, atherosclerosis, hypertension, and
heart hypertrophy as well as metabolic and degenerative
diseases [13, 14].
e focus of this paper was to elucidate the in�uence
and role of dietary SFA and TFA intake in lipotoxicity in the
liver and the cardiovascular, endothelial, and gut microbiota
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systems as well as in insulin resistance and endoplasmatic
reticulum stress.
2. Insulin Sensitivity and Resistance
Insulin is an anabolic hormone that exerts several important
metabolic eﬀects. Insulin regulates glucose homeostasis at
several levels, including decreasing hepatic glucose synthesis
and increasing peripheral glucose uptake, primarily inmuscle
and adipose tissue. Moreover, this hormone stimulates lipo-
genesis and the synthesis of protein in hepatic and adipose
tissues, while reducing lipolysis and proteolysis [15].
Events that occur aer insulin binds to its receptor
are highly regulated and speci�c and can be in�uenced by
numerous factors such as the dietary composition, including
the quantity and type of fatty acids [16, 17].
Although several mechanisms have been implicated in
the development of insulin resistance [16], more studies are
necessary to elucidate the link between the mechanisms of
insulin resistance and fatty acid intake.
Increased lipid availability reduces insulin-stimulated
glucose consumption in skeletal muscle. is eﬀect is gener-
ally explained as a fatty acid-mediated inhibition of insulin
signaling [15]. Moreover, in a recent investigation it was
shown that a palatable hyperlipidic diet, rich with SFA, causes
obesity and aﬀects brain glucose metabolism in rats [18].
In a clinical study, short-term elevation of free fatty acids
(FFAs) induced insulin resistance, which occurs primarily at
the cellular level in skeletal muscle [17].
A chronic increase in plasma FFA levels is harmful as
shown by the important eﬀects of these dietary components
in pancreatic beta cell lipotoxicity. Fatty acid derivatives can
interfere with the function of these cells and ultimately lead
to their death through lipoapoptosis [19].
Fatty acids in excess not only induce hepatic insulin
resistance but also impair insulin clearance in vitro and in vivo
in animals [20, 21] and humans [22].is leads to the typical
hyperinsulinemia observed in insulin-resistant states and in
nonalcoholic fatty liver disease (NAFLD) [23, 24].
Several studies performed by our group have demon-
strated that long-term interdisciplinary therapy reduces
fat intake, in particular SFA, in obese adolescents. e
intervention resulted in decreased visceral fat and tumor
necrosis factor-alpha (TNF-𝛼𝛼) and interleukin-6 (IL-6)
levels and increased levels of interleukin-10 (IL-10) and
adiponectin, accompanied by a reduction in homeostatic
model assessment-insulin resistance (HOMA-IR) and the
occurrence of associated diseases [25–28]. In the context of
these results, we proposed that the altered insulinemic status
could be considered to play a key role in the development of
several cardiometabolic risk comorbidities [12, 29–31].
In one review article, fatty acids were said to aﬀect insulin
secretion as a function of the chain length. us, insulin
secretion increases as a function of longer carbon chains
and decreases as a function of the degree of unsaturation.
ese �ndings suggest that SFA and TFA in�uence insulin
resistance [32].
In an animalmodel, although TFA ingestion had no eﬀect
on fasting plasma glucose, insulin levels, or oral glucose tol-
erance, it signi�cantly decreased insulin-stimulated glucose
uptake in muscles compared to polyunsaturated fatty acids
(PUFAs) [33].
In a cross-sectional study of individuals with high car-
diometabolic risk, the association of TFA intake with insulin
resistance was demonstrated. e authors speculated that
TFA interferes with insulin signaling predominantly via
intracellular kinases, which alter insulin receptor substrates
[34].
Activation of intracellular kinases, such as inhibitor of
nuclear factor-𝜅𝜅B kinase (IKK) and c-Jun N-terminal kinase
(JNK), alters insulin receptor substrates and decreases insulin
sensitivity. Additionally, it is important to note that activation
of transcription factors can contribute to reduced glucose
uptake by the expression of proin�ammatory cytokines, such
as TNF-alpha and IL-6, causing impairment in the insulin
receptor phosphorylation (Figure 3) [35].
e deleterious role of SFA in glucose and lipid
metabolismhas been previously shown. A partial explanation
is that SFA increases production of cytokines such as TNF-
𝛼𝛼 and IL-6 through hypertrophic adipocytes and in�ltrating
macrophages, and these cytokines cause the deterioration of
insulin sensitivity [35].
Treatment of primary mouse hepatocytes and pancreatic
cells with palmitic acid, an SFA, caused sustained JNK
activation and insulin resistance. Moreover, the palmitic
acid treatment inhibited glucose-induced insulin gene tran-
scription. is eﬀect may be mediated by interference of
autocrine insulin signaling through the phosphorylation of
insulin receptor substrates 1 and 2 at sites that interfere
with their binding to activated insulin receptors [36]. It
has been proposed that long-chain saturated fatty acids,
such as palmitic acid, can trigger insulin resistance in
both primary hepatocytes and pancreatic 𝛽𝛽-cells in a JNK-
dependent manner. e JNK phosphorylation site on IRS-2
may be functionally equivalent to Ser-307 of IRS-1 (Figure 3).
Moreover, JNK might also be involved in negative regulation
of insulin synthesis or signaling within the pancreatic 𝛽𝛽-cells,
the central site of blood glucose regulation. us, palmitic
acid can be considered to be a potent activator of JNK in
cultured hepatocytes and 𝛽𝛽-cells, leading to IRS-1 and IRS-
2 Ser/r phosphorylation [36].
3. Hepatic Injury
e emergence of obesity has led to substantial prevalence
of NAFLD. Worldwide, the prevalence of NAFLD ranges
between 10% and 39%. However, the prevalence of NAFLD
is increased in certain populations: the condition aﬀects
approximately 50% of diabetics, 57% to 74% of the obese,
and up to 90% of morbidly obese people. erefore, in the
last decade, this disease has been recognized as an emerging
clinical problem in obese patients [37, 38]. e pathogenesis
of NAFLD is unclear, but there is evidence that insulin
resistance, in�ammation, and genetic and dietary factors, as
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well as lifestyle, exert key roles in the development of NAFLD
[39].
Several studies have revealed an association between
obesity and NAFLD progression. In NAFLD patients, the
adipocytes of the visceral tissue demonstrate elevated lipoly-
tic activity, promoting a high in�ux of FFA into the por-
tal vein [37, 38, 40]. Moreover, the literature shows an
association between visceral adipocytes and the hepatic
cellular in�ammatory process [41]. It is believed that the
physiopathology of NAFLD may be driven by several forms
of hepatic injury.e �rst hypothesis involved in the develop-
ment of NAFLD is related to insulin resistance.e in�uence
of genetic and environmental factors can promote peripheral
insulin resistance, which leads to increased levels of nones-
teri�ed fatty acids (NEFAs). Subsequently, a high in�ux of
these fatty acids into hepatocytes promotes increased hepatic
de novo lipogenesis. When the rate of lipogenesis exceeds
the rate of 𝛽𝛽-oxidation of fatty acids and the exportation of
VLDL, hepatic fat accumulation is observed (Figure 1) [40].
e exactmechanisms that promote the progression from
steatosis to steatohepatitis have not yet been completely
elucidated. However, it is clear that apoptosis can be a
pathophysiologic marker of nonalcoholic steatohepatitis in
some steatotic patients.
It has been proposed that the accumulation of FFA, espe-
cially saturated fatty acids, in the hepatocytes can promote
apoptosis by diverse pathways. ese may include ROS-
induced stress that aﬀects the mitochondrial membranes,
endoplasmic reticulum, and lysosomes. Lipid peroxidation
increases the levels of reactive oxygen species, which may be
partially responsible for hepatocyte dysfunction [42] (Figure
1).
Apoptosis of the hepatocytes can occur via extrinsic or
intrinsic pathways.e extrinsic pathway is induced by death
ligands such as Fas (a key death receptor belonging to the
tumor-necrosis-factor- (TNF-) receptor family) and TRAIL
(TNF-related apoptosis-inducing ligand). In contrast, the
intrinsic pathway of cell death is activated by the intracellular
stress ofmembrane-bound organelles, such as ER, lysosomes,
and mitochondria [43].
Saturated fatty acids activate complex intracellular path-
ways, including the activation of Toll-like receptor 4 (TLR-
4), which subsequently stimulates TNF-𝛼𝛼 production. TNF-
𝛼𝛼 consequently activates the JNK pathway [40], leading
to the upregulation of the proapoptotic BH3-only protein
PUMA (p53-upregulated modulator of apoptosis). PUMA
then associates with BIM (Bcl-2-interacting mediator of cell
death) to activate BAX, a proapoptotic protein of the BCL-2
(B-cell lymphoma 2) family. e end result of this pathway is
mitochondrial dysfunction, activation of the caspase cascade,
and cell death [43].
e TFA obtained in the diet accumulates in cellular
triacylglycerols and phospholipids. Chronically excessive tri-
acylglycerol accumulation in tissues such as the liver, muscle,
and pancreatic beta cells leads to a protective response
involving adaptation of the adipocytes, and this response
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includes activation of several in�ammatory pathways that
promote adipose tissue insulin resistance [34].
Toll-like receptors (TLRs) are classical pattern recogni-
tion receptors of the innate immune response. Two of these
receptors, TLR4 and TLR2, are activated by SFA but inhibited
by docosahexaenoic acid [44].
TLR4 activates both MyD88-dependent and -independ-
ent pathways. e MyD88-dependent pathway is initiated
by the recruitment of TIRAP, an adaptor between the TIR
domain of TLR-4 and MyD88, followed by activation of
the IRAK family of protein kinases and subsequent phos-
phorylation of TRAF6. In the MyD88-independent pathway,
the activation of TLR-4 requires the participation of TRAM
to recruit TRIF, which then activates TRAF6 and TRAF3.
TRAF6, directly or via TAK1, stimulates the IKK complex
which promotes phosphorylation of IkB leading to activation
of nuclear factor 𝜅𝜅B (NF-𝜅𝜅B) (Figure 3) [45].
FFAs activate TLR-4 receptors in macrophages and
adipocytes, which results in increased proin�ammatory
cytokine gene and protein expression [46]. Recently, it has
been demonstrated that saturated fatty acids can induce
TNF-𝛼𝛼 expression bymacrophages by activating theMyD88-
independent pathway [47].
TLR4 activation plays a central role in the in�ammatory
process, activating in�ammatory cytokine gene transcrip-
tion and also inducing endoplasmic reticulum stress. e
activation of TLR4 by LPS induces a potent endoplasmic
reticulum stress and unfolded protein response through the
PERK/eIF2𝛼𝛼 and IRE1𝛼𝛼/XBP1 pathways (Figure 4) [48].
NFkB, a transcription factor known as a mediator of immune
and antiapoptotic responses, is activated by the accumulation
of membrane proteins in the ER. Speci�cally, the accumu-
lated proteins lead to the production of reactive oxygen
intermediates, which activate NFkB by degradation of IkB.
Recently, it has been proposed that the phosphorylation of
eIF2a is required for the triggering of NFkB. In summary,
the apoptotic process involves the activation of the gene for
C/EBP homologous protein (CHOP), also known as growth
arrest and DNA damage-inducible gene 153 (GADD153)
(Figure 4); the activation of the cJUN NH2-terminal kinase
(JNK) pathway, which is mediated by the formation of the
inositol-requiring 1 (Ire1)-TNF receptor-associated factor 2
(TRAF2)-apoptosis signal-regulating kinase1 (ASK1) com-
plex; and the activation of the ER-associated caspase-12. In
humans, these apoptotic pathways eventually lead to the
activation of caspase-3 [49].
e second hypothesis of NAFLD physiopathology refers
to the release of fatty acids from dysfunctional and insulin-
resistant adipocytes. is release causes lipotoxicity, mainly
to visceral adipose tissue [40]. e visceral adipose tissue
is in�ltrated by in�ammatory cells, including macrophages
and other immune cells, which increase secretion of
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in�ammatory adipokines such as leptin, IL-6, TNF-𝛼𝛼, and
angiotensinogen, aswell as reducing secretion of adiponectin,
an anti-in�ammatory adipokine [50]. Insulin resistance of the
visceral adipose tissue is associated with increased lipolytic
activity, which increases the levels of FFA in the portal
circulation, potentially resulting in hepatotoxicity (Figure 1)
[40, 41].
Experimentally, it has been demonstrated that the
decreased secretion of adiponectin in obesity alters lipid
metabolism and insulin sensitivity in the liver. However,
administration of recombinant adiponectin to adiponectin-
de�cient obesemice fed a high-fat diet dramatically alleviated
hepatomegaly, steatosis, and in�ammation [51].
At the clinical level, adipose tissue insulin resistance
contributes to type 2 diabetes mellitus and CVD. On the
other hand, decreasing plasma FFA concentration by admin-
istration of acipimox, a nicotinic acid analogue that inhibits
adipose tissue lipolysis, rapidly improves muscle insulin
sensitivity [52].
e potential ability of FFA to alter skeletal muscle glu-
cose metabolism was �rst proposed more than 50 years ago
[53] and has been widely investigated. e FFA-induced
eﬀects on this tissue do not appear to be the result of
the accumulation of intramyocellular lipids per se. Rather,
skeletal muscle insulin resistance is closely correlated with
the presence of a variety of toxic metabolites derived from
incomplete oxidation of fatty acids, such as acylcarnitines and
long-chain fatty acyl CoAs, ceramides, and/or diacylglycerols
[54, 55].
Oxidative stress is believed to be an important factor
in the development of NAFLD [56]. e importance of
fatty acids in this process is clear from the observation that
biological membranes adjust their composition according to
the fatty acid content of dietary fat [57]. Dietary fatty acids
can in�uence the susceptibility of cells to oxidative stress,
perhaps due to changes in the fatty acid composition of the
cellular membranes [58].
Intake of high levels of SFA is associated with increased
lipid content in the liver [18, 59–61] and with liver dysfunc-
tion. is dysfunction is thought to be caused by an increase
in the production in reactive oxygen species, which leads to
damage of the hepatic mitochondria. In addition, SFA intake
exceeding 10% of total energy promotes insulin resistance,
which plays a key role in the development of NAFLD [62].
e association between high intake of SFA and choles-
terol with NAFLD has been previously demonstrated [63,
64]. SFAs promote endoplasmic reticulum stress as well
as hepatocyte injury. Accumulation of SFA in the liver
leads to an increase in markers associated with endoplas-
mic reticulum stress, such as reactive oxygen species and
caspase activation. ese biomarkers are associated with
liver dysfunction. Moreover, the positive correlation between
SFA intake and insulin resistance, which plays a key role in
the development of NAFLD, has been demonstrated. ese
correlations suggest that limiting SFA intake is a valuable
nutritional strategy for the prevention and treatment of
NAFLD [62].
Papandreou et al. [64] demonstrated that the SFA intake
was directly proportional to the degree of hepatic steatosis. In
their study, multiple regression analysis of factors associated
with fatty liver showed thatHOMA-IR and SFAwere themost
signi�cant factors for this condition a�er adjustment for age,
gender, and diet.Wehave also observed an association among
SFA intake, NAFLD, and orexigenic neuropeptides [26].
Diets rich in fatty acids, mainly SFA and TFA, as well
as carbohydrate-rich diets, favor an acute increase in insulin
resistance independent of adiposity. High SFA intake may
also promote steatohepatitis directly by modulating hep-
atic triacylglycerol accumulation and oxidative activity and
indirectly by aﬀecting insulin sensitivity and postprandial
triacylglycerol metabolism [64].
In clinical studies performed by our research group, we
showed a positive correlation between calories derived from
SFA intake and visceral fat in NAFLD patients [23, 26].
ese data suggested that composition of the diet exerts
an important role in the development of NAFLD and its
treatment and that it is essential to consider excessive SFA
intake as a critical risk factor for development ofNAFLD [26].
Another potentially important mechanism for lipotoxic-
ity of TFA in the liver is their eﬀects on hepatic antioxidant
enzymes. Reactive oxygen species (ROS) form as natural
byproducts from the normal metabolism of oxygen and have
important roles in cell signaling and homeostasis. However,
during times of environmental stress, ROS levels can increase
dramatically. is may result in signi�cant damage to cell
structures. Cumulatively, this is known as oxidative stress.
Endogenous antioxidant enzymes, including superoxide dis-
mutase (SOD), catalase (CAT), and glutathione peroxidase
(GPx), are essential to defend against ROS. e removal of
reactive oxygen substances is accomplished by enzymatic and
nonenzymatic reactions in biological systems. In enzymatic
reactions, SOD converts superoxide anions to hydrogen
peroxide (H2O2), and H2O2 can be rapidly degraded by CAT
and GPx to H2O [65–67].
High-fat diets can cause the formation of toxic interme-
diates that can inhibit the activity of antioxidant enzymes,
resulting in the accumulation of O2 radicals and H2O2,
which subsequently form hydroxyl radicals [68, 69]. TFAs are
associated with a decrease in the eﬃciency of the antioxidant-
enzymatic system and therefore with the increase of oxidative
stress in rat livers. TFA may impart their eﬀect by enhancing
intrinsic signaling mechanisms leading to a chronic, pro-
in�ammatory state. Consumption of diets high in TFA may
induce long-term progressive changes in the antioxidant
enzyme’s activities [70].
Finally, another pathway by which excessive TFA intake
could cause hepatic injury is through eﬀects on lipid
metabolism. In vitro, TFAs alter the secretion, lipid compo-
sition, and size of apolipoprotein B-100 (apoB-100) particles
produced by hepatic cells [71] (Figure 2). Speci�cally, these
cells fail to synthesize the apolipoprotein, which is required
to package and export fat from the liver. erefore, the liver
accumulates triacylglycerol. In a study in which male Wistar
rats were fed a high-fat diet including 20% fresh soybean
oil diet, 20% oxidized soybean oil diet, or 20% margarine
diet for 4 weeks, the highest in�ammatory response in
the liver was induced by the margarine diet. e authors
demonstrated that oxidized edible oils fed to rats for four
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weeks increased lipid peroxidation in the liver compared
with rats fed nonoxidized oils. ese results suggest that a
strong relationship exists between the consumption of TFA in
the oxidized oils and lipid peroxidation. is study provides
evidence for a direct eﬀect of TFA on liver dysfunction caused
by disturbances in hepatic lipid metabolism. e resulting
NAFLD is a key component of cardiometabolic risk. is
evidence suggests that TFA may in�uence the risk factors for
CVD [70].
us, the link between dysfunctional adipocytes and the
liver involves several pathways that combine to promote the
development of lipotoxic liver disease, a term that more
accurately describes the pathophysiology of nonalcoholic
steatohepatitis.
In fact, hepatic steatosis is considered to be a hepatic
manifestation of cardiometabolic risk. is condition is
associated with obesity, insulin resistance, hypertension, and
dyslipidemia. Clinical studies corroborate the relationship
between NAFLD and CVD. Speci�cally, obese NAFLD
patients were shown to have a greater intima-media thickness
(IMT), a subclinical marker of the atherosclerotic process,
compared to non-NAFLD patients [72]. In this context,
our research group performed a study that involved one
year of interdisciplinary intervention in obese adolescents.
e results indicated that the improvement of HOMA-IR
was an independent predictor of carotid IMT changes in
this population [30]. As previously discussed, hyperinsuline-
mia from increased insulin secretion and decreased insulin
clearance correlates with the severity of hepatic steatosis,
and chronically elevated plasma insulin levels may promote
atherogenesis [73, 74]. Hyperglycemia, per se, and the typical
atherogenic dyslipidemia in NAFLD driven by oversecretion
of VLDL are established factors for CVD. However, whether
NAFLD and CVD are mechanistically related or merely both
associated with lipotoxicity remains to be established.
4. Cardiovascular Risk
Studies suggest multiple possible mechanisms that might
mediate the association of TFA with CVD. ree main
pathways for these physiological eﬀects have been proposed:
serum lipid concentrations, systemic in�ammation, and
endothelial cell function [3, 75].
Consumption of industrial TFA increases the blood
concentrations of low-density lipoprotein (LDL), triacylglyc-
erols, and Lp(a) lipoprotein while decreasing the levels of
high-density lipoprotein (HDL) and reducing the particle size
of LDL cholesterol. Furthermore, consumption of TFA can
increase the ratio of total cholesterol to HDL cholesterol, a
powerful predictor of CVD risk [3, 76]. us, TFAs have
markedly adverse eﬀects on serum lipid pro�les.
As described previously, there is an important relation-
ship between intake of TFA and incidence of CVD. However,
the eﬀects exceed those predicted by the changes in serum
lipids alone, suggesting that TFAs in�uence other risk factors
for CVD [77]. Speci�cally, in addition to their eﬀects on
lipid/lipoprotein pro�les, TFA consumption is known to
in�uence multiple risk factors including increased systemic
in�ammation [78], increased thrombogenesis, and reduced
endothelial function [2], all of which, in combination or
individually, contribute to increased cardiovascular risk.
Experimental studies suggest that TFAs exert their multiple
eﬀects by in�uencing metabolic and signaling pathways in
hepatocytes, monocytes, adipocytes, and endothelial cells.
e precise molecular pathways through which TFAs in�u-
ence these cell types are not well established [77].
e eﬀect of TFA on systemic in�ammation can be
partially explained by the in�uence of these fatty acids on
the prostaglandin balance. e eﬀects on these processes
can in�uence thrombogenesis and impair the activity of Δ
desaturase, the enzyme responsible for the conversion of
linoleic acid to arachidonic acid and other n-6 PUFA. us,
this inhibition alters essential fatty acid metabolism [79].
Moreover, in an animal model of excess TFA consumption,
changes in the phospholipid fatty acid composition in the
aorta were observed [80] (Figure 2). TFAs have been associ-
ated with the activation of systemic in�ammatory responses,
including substantially increased levels of IL-6, plasminogen
activator inhibitor-1 (PAI-1), TNF-𝛼𝛼, TNF receptors, and
monocyte chemoattractant protein-1, and with increased
levels of several markers of endothelial activation, such as
soluble intercellular adhesion molecule 1, soluble vascular-
cell adhesion molecule 1, and E-selectin [2, 3, 81] (Figure 2).
In controlled trials, however, TFA did not increase all
in�ammatory markers [78, 82]. Oxidative stress may also
explain the high risk of CVD associated with industrial TFA
intake [83].
Oxidative stress induced by free radicals has been asso-
ciated with the development of several diseases including
CVDs, most likely through a vascular proin�ammatory
response [84]. However, further research is necessary to
fully elucidate the implications of the eﬀects of TFA on
some markers of oxidative stress. Although the possible
mechanisms that link TFA and oxidative stress are unknown,
eﬀorts to eliminate partially hydrogenated oils from the diet
remain necessary and important to reduce the burden of
CVD [70].
e third pathway linking TFA and CVD refers to
the possible in�uence of TFA on endothelial cell function.
Endothelial nitric oxide synthase (eNOS) synthesizes nitric
oxide (NO) in response to many stimuli, such as �uid shear
stress and insulin. ese stimuli increase NO production
in endothelial cells through an insulin receptor substrate-
1 (IRS-1-) and phosphatidylinositol 3-kinase (PI3-kinase-)
dependent pathway that causes phosphorylation of endothe-
lial nitric oxide synthase (eNOS) by Akt [85].
A review of the in�uences of fatty acids on endothelial
cell function suggested that increased ingestion of fatty acids
impairs endothelial cell insulin signaling and NO produc-
tion through the activation of the IKK/NF-𝜅𝜅B pathway.
Furthermore, an experimentally induced elevation of the
concentration of plasma FFA in humans alters endothelial
function [46].
It has also been shown that the dietary SFA palmitate
attenuates endothelial insulin signaling and NO production
by �rst activating NF-𝜅𝜅B signaling, which results in a reduc-
tion in IRS-1/pAkt/peNOS signaling [77].
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e reduction of SFA intake is considered a primary
goal for decreasing the risk of CVD. A low SFA diet was
demonstrated to be associated with the reduced progression
of coronary atherosclerosis [86, 87].
e eﬀect of SFA intake on the plasma lipid risk factors
and eﬀects on CVD are similar to those described for TFA
intake. However, SFA ingestion is particularly associated with
activation of the TLR pathways.
In a clinical investigation, TLR-4 and TLR-2 expression
and activity were increased in the monocytes of patients
with cardiometabolic risk. e pathways regulated by these
receptors could contribute to the patients’ high risk for CVD
[88].
5. Endoplasmic Reticulum Stress
Lipid peroxidation is de�ned by a biochemical cascade that
results in oxidative degradation of PUFA.When the lipid per-
oxidation occurs in biological membranes, it causes impaired
membrane function and structural integrity, decreases in
membrane �uidity, and inactivation of several membrane
enzymes [89]. Niu et al. [90] reported that phospholipids
derived fromTFAhad a highermembrane cholesterol aﬃnity
than their cis-analogues. us, TFA ingestion could alter cell
membrane structure, organization, and composition in an
ROS-mediated manner.
A recent animal experiment indicated that TFA reduced
the membrane �uidity of fat cells and impaired cell function.
e suggested mechanism involved production of additional
reactive oxygen species associated with the increase in lipid
peroxidation in the groups fed the TFA diet [91]. A high-
fat diet induces endoplasmic reticulum stress (ER), which
activates IKK and JNK, thereby impairing insulin signaling
[92].
Recent evidence suggests that lipotoxicity in hepatocytes
involves ER stress and JNK-mediated apoptosis [93, 94].
Disturbances in the normal functions of the ER lead to
an evolutionarily conserved cell stress response, the unfolded
protein response, which is aimed initially at compensating for
damage but can eventually trigger cell death if ERdysfunction
is severe or prolonged. Although the mechanisms by which
ER stress leads to cell death are not completely understood,
some of them have been described in the literature. A study
of mice de�cient in caspase-12 showed that while the cells
of these mice were resistant to ER stress-induced apoptosis,
apoptosis of the cells occurred normally in response to other
death stimuli [95]. Based on these data, it was proposed that
other pathways leading to cell death by ER stress should
be explored. Increases in apoptotic proteins, such as BIM,
BAK, and PUMA,were observed during ER stress, suggesting
a connection between stress signals and the proapoptotic
switch that occurs when cellular homeostasis is irreversibly
altered, �nally leading to cell death [96, 97].e ER responds
to the burden of unfolded proteins in its lumen by acti-
vating intracellular signal transduction pathways, generically
termed the unfolded protein response (UPR). Another sug-
gested mechanism is that the three UPR branches provide
opposing signals and that the relative timing of their induc-
tion shis the balance between cytoprotection and apoptosis
as unmitigated ER stress persists. Speci�cally, IRE1 signaling
attenuates upon prolonged ER stress, and PERK (protein
kinase RNA-like endoplasmic reticulum kinase) signaling
induces its own deactivation via GADD34 expression (Figure
4). Both pathways thus contain intrinsic timers that are likely
to contribute to the life-or-death decision [98].
Important roles for ER-initiated cell death pathways have
been recognized for several diseases, including hypoxia,
ischemia/reperfusion injury, neurodegeneration, heart dis-
ease, and diabetes [99].
Studies suggest that cytokines, as well as elevated lipids,
especially long-chain SFA,may induce ER stress in pancreatic
𝛽𝛽-cells and liver cells. SFA-induced 𝛽𝛽-cell death has been
shown to be related to the activation of caspases [94, 100].
Elevated lipids also induce apoptosis in a number of cell
types, suggesting that ER stress may be an early component
of lipotoxicity [94].
A study of cultured H4IIE liver cells investigated the
in�uence of SFA and TFA in the apoptosis process and the
role of the ER stress-induced activation of caspases. e
authors observed that SFA induced ER stress and increased
both caspase-9 and caspase-3 activity (Figure 4). e authors
hypothesized that saturation, per se, plays a role in lipotoxicity
in liver cells [94].
6. Gut Microbiota
e human gut contains a massive number of microor-
ganisms or microbiota. Several mechanisms have been pro-
posed to link gut �ora to obesity, including the role of the
gut microbiota in increasing energy extraction from indi-
gestible dietary polysaccharides [101] and elevating plasma
lipopolysaccharide levels, resulting in chronic low-grade
in�ammation [102].
e intestinal �ora exerts an important role in normal
gut function and maintenance of health, and the dietary
composition can in�uence the se�uence and the nature of col-
onization. Cani et al. [103] found that a high-fat diet resulted
in a signi�cant change in the composition of the dominant
bacterial populations within the gut micro�ora, including a
decrease in the number of Bi�do�acteria, Eubacterium, rectal
Clostridium coccoides group, and Bacteroides, thus favoring
an increase in the gram-negative to gram-positive ratio. is
change in gut micro�ora composition was associated with
a signi�cant increase in plasma lipopolysaccharide (LPS)
levels, fat mass, body weight gain, liver hepatic triglyceride
accumulation, insulin resistance, and diabetes [103, 104]. In
addition, de Wit et al. [105] observed that a high saturated
fatty acid diet enhanced an over�ow of dietary fat to the distal
intestine, which aﬀected the gut microbiota composition.
is alteration was associated with obesity development and
hepatic steatosis.
e gutmicrobiota of obese individuals or those consum-
ing a high content of saturated fatty acids contains predomi-
nantly gram-negative bacteria rich in LPS. Toll-like receptors
in the cell membranes recognize LPS in the circulation
(endotoxemia) and activate speci�c kinases, which lead to
insulin resistance.ese pathways also activate NF-𝜅𝜅B, which
results in the expression of in�ammatory genes. Similar to
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LPS, saturated fatty acids are also recognized by membrane
receptors that trigger proin�ammatory signaling pathways
[102, 106].
Recently, our group demonstrated a positive correlation
between plasma endotoxin concentration and both proin-
�ammatory cytokines (especially IL-6) and insulin resis-
tance in obese adolescents. Importantly, aer long-term (one
year) interdisciplinary therapy, endotoxemia, proin�amma-
tory status, and insulin resistance were decreased [25]. ese
results showed the eﬀectiveness of making lifestyle changes
(i.e., nutritional modi�cation) in reducing the proin�amma-
tory state in obese individuals [107, 108].
7. Conclusion
ese experimental and clinical �ndings indicate that excess
intake of both SFA and TFA can promote lipotoxicity in
several target organs by direct eﬀects, represented by in�am-
matory pathways, and indirect eﬀects, including important
alterations in the gut microbiota with implications for the
endotoxemia process (Figure 5). Interplay between these
pathways perpetuates a feedback process in which an in�am-
matory state elevates the risk factors for diverse diseases.
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